Merck
Search Within
Applied Filters:
Keyword:'y0000648'
Showing 1-30 of 86 results for "

y0000648

" within Papers
Kiyoshi Kikuchi et al.
International journal of molecular sciences, 14(9), 18899-18924 (2013-09-26)
Stroke is a major cause of mortality and disability worldwide. The main cause of stroke is atherosclerosis, and the most common risk factor for atherosclerosis is hypertension. Therefore, antihypertensive treatments are recommended for the prevention of stroke. Three angiotensin receptor
A Soliman et al.
Transplantation proceedings, 44(10), 2936-2939 (2012-12-01)
This double-blind trial followed 16 patients with autosomal dominant polycystic kidney disease (ADPKD) who received telmisartan or sirolimus plus telmisartan for 24 months. The 6-month pilot study showed a promising effect of sirolimus. The primary metric of this 2-year study
Guangrong Zou et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 37(3), 223-234 (2014-10-02)
Spontaneously hypertensive rats (SHR) was used to study left ventricular hypertrophy (LVH) and its dynamic change after the interventions with Telmisartan and Amlodipine. The results showed that the expression of TRPC1, CaN and NFATC3 increased gradually with the pathogenesis and
Kota Sato et al.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 23(10), 2511-2519 (2014-09-24)
Telmisartan, an angiotensin receptor blocker with high lipid solubility, also called metabo-sartan, not only reduces blood pressure (BP), but also ameliorates inflammation in the cerebral cortex and in adipose tissue. We examined the effects of telmisartan on inflammatory responses of
Pitchai Balakumar et al.
Current diabetes reviews, 8(3), 183-190 (2012-03-21)
Diabetic nephropathy, a complex disorder with heterogeneous etiologies, remains one of the most threatening diseases worldwide. There were around 177 million people with diabetes mellitus worldwide, and it has been estimated to be increased to 360 million by 2030. Given
Li Li et al.
Diabetes, 62(3), 762-774 (2012-12-15)
The mechanisms of the improvement of glucose homeostasis through angiotensin receptor blockers are not fully elucidated in hypertensive patients. We investigated the effects of telmisartan on insulin signaling and glucose uptake in cultured myotubes and skeletal muscle from wild-type and
Mahshid Dehghan et al.
Circulation, 126(23), 2705-2712 (2012-12-06)
Diet quality is strongly related to cardiovascular disease (CVD) incidence, but little is known about its impact on CVD events in older people at high risk of CVD and receiving effective drugs for secondary prevention. This study assessed the association
Eun-Sook Jeong et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(1), 10-18 (2014-07-19)
1. Fimasartan is an angiotensin receptor II antagonist used to treat patients with hypertension. This drug is mainly excreted into bile as either the parent compound or a glucuronide conjugate. In this study, we examined the glucuronidation of fimasartan and
Ambulatory central blood pressure: a new opportunity for mechanistic and clinical cardiovascular research.
Giuseppe Mancia
Hypertension (Dallas, Tex. : 1979), 61(6), 1148-1149 (2013-05-01)
Habib Eslami et al.
Neuroscience letters, 558, 31-36 (2013-11-12)
Telmisartan is an angiotensin II type 1 receptor blocker and partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ). Here, we investigated the protective capacity of telmisartan against high glucose (HG)-elicited oxidative damage in PC12 cells. The activity of lactate dehydrogenase
A quest--halting the progression of autosomal dominant polycystic kidney disease.
David H Ellison et al.
The New England journal of medicine, 371(24), 2329-2331 (2014-11-18)
Yasunori Iida et al.
PloS one, 7(12), e49642-e49642 (2012-12-12)
Despite the importance of the renin-angiotensin (Ang) system in abdominal aortic aneurysm (AAA) pathogenesis, strategies targeting this system to prevent clinical aneurysm progression remain controversial and unproven. We compared the relative efficacy of two Ang II type 1 receptor blockers
Ming Wang et al.
Chinese journal of integrative medicine, 20(10), 758-763 (2014-07-31)
To observe the time-effect relation of extracts from ginseng, notoginseng and chuanxiong on angiotensin II (Ang II)-induced senescence of vascular endothelial cells and explore the feature of Chinese medicine against vascular diseases. Human umbilical vein endothelial cells (HUVECs) cultured in
Vicente E Torres et al.
The New England journal of medicine, 371(24), 2267-2276 (2014-11-18)
Hypertension develops early in patients with autosomal dominant polycystic kidney disease (ADPKD) and is associated with disease progression. The renin-angiotensin-aldosterone system (RAAS) is implicated in the pathogenesis of hypertension in patients with ADPKD. Dual blockade of the RAAS may circumvent
Jordan E Lake et al.
PloS one, 8(3), e58135-e58135 (2013-03-22)
Visceral adiposity in the setting of HIV infection and antiretroviral therapy (ART) is not fully understood, and treatment options remain limited. Telmisartan, an angiotensin receptor blocker and partial PPAR-γ agonist, has been shown to decrease visceral fat and improve metabolic
Holger Cynis et al.
International journal of experimental pathology, 94(3), 217-225 (2013-04-09)
Inflammation is an integral part of non-alcoholic fatty liver disease (NAFLD), the most prevalent form of hepatic pathology found in the general population. In this context, recently we have examined the potential role of Glutaminyl Cyclases (QC and isoQC), and
Hirotoshi Kakuta et al.
The Journal of pharmacology and experimental therapeutics, 349(1), 10-20 (2014-01-16)
A proportion of angiotensin II type 1 receptor blockers (ARBs) improves glucose dyshomeostasis and insulin resistance in a clinical setting. Of these ARBs, telmisartan has the unique property of being a partial agonist for peroxisome proliferator-activated receptor γ (PPARγ). However
Yasmeen M Attia et al.
Parasites & vectors, 6, 199-199 (2013-07-09)
Hepatic schistosomiasis is considered to be one of the most prevalent forms of chronic liver disease in the world due to its complication of liver fibrosis. The demonstration of the pro-fibrogenic role of angiotensin (Ang) II in chronic liver disease
Anne Bayer et al.
Environmental science and pollution research international, 21(18), 10830-10839 (2014-06-06)
Pharmaceuticals and other anthropogenic trace contaminants reach wastewaters and are often not satisfactorily eliminated in sewage treatment plants. These contaminants and/or their degradation products may reach surface waters, thus influencing aquatic life. In this study, the behavior of five different
Yves Lacourcière
Clinical and experimental hypertension (New York, N.Y. : 1993), 35(1), 50-60 (2012-08-08)
The aim of this review was to compare telmisartan and valsartan in the treatment of hypertension. PubMed searches were conducted to identify randomized trials (n = 14) comparing the two agents, alone or combined with hydrochlorothiazide. With one exception, all
Roland E Schmieder et al.
Journal of nephrology, 24(3), 263-273 (2011-03-05)
Renal dysfunction can be regarded as a continuum that extends from endothelial dysfunction to microalbuminuria, macroalbuminuria, end-stage renal disease and ultimately to death. All stages of this continuum are associated with progressively increasing cardiovascular risk. Preventing the development and progression
Rainer Düsing et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(1), 41-47 (2013-01-04)
Poor adherence to antihypertensive drug treatment is common and is often associated with marked prolongations of the dosing interval. Hence, selecting a treatment that has the potential to provide a sustained blood pressure (BP)-lowering effect is important. The objective of
Massimo Volpe
Expert review of cardiovascular therapy, 10(8), 1061-1072 (2012-10-04)
Angiotensin II receptor blockers (ARBs) inhibit the renin-angiotensin system. As a result, these agents provide beneficial effects in terms of cardiovascular (CV) and renal protection, independent of their blood pressure-lowering effects. Telmisartan and valsartan are the most intensively studied ARBs
Taro Shindo et al.
Biological & pharmaceutical bulletin, 35(12), 2141-2147 (2012-12-05)
Telmisartan, an angiotensin type 1 receptor blocker, is used in the management of hypertension to control blood pressure. In addition, telmisartan has a partial agonistic effect on peroxisome proliferator activated receptor γ (PPARγ). Recently, the effects of telmisartan on spatial
Tomoko Kurata et al.
Translational stroke research, 6(2), 107-115 (2014-01-18)
Telmisartan is expected to reduce not only the level of blood pressure but also neuroinflammation and neurotoxicity via pleiotrophic effects as a metabo-sartan. We examined the effects of telmisartan on Alzheimer's disease (AD) pathology in spontaneously hypertensive rat stroke resistant
Paolo Verdecchia et al.
Hypertension (Dallas, Tex. : 1979), 65(1), 108-114 (2014-10-22)
Excessively high and low achieved blood pressure (BP) may be associated with a bad outcome in patients with coronary artery disease, the J curve phenomenon. The effect of BP changes from baseline in relation with the subsequent risk of stroke
Giuseppe Derosa et al.
Expert review of cardiovascular therapy, 9(12), 1499-1503 (2011-11-23)
A combination of two drugs as initial treatment in patients with a high or very high cardiovascular risk profile is recommended. Nifedipine extended release (GITS) is a calcium-channel antagonist known to be metabolically neutral, to mildly slow the development of
N Suksomboon et al.
Journal of clinical pharmacy and therapeutics, 37(3), 319-327 (2011-08-19)
Telmisartan is an angiotensin receptor blocker (ARB) originally developed for the treatment of hypertension. It can also partially activate peroxisome proliferator-activated receptor (PPAR)-γ, which may improve insulin sensitivity. This effect may prove useful in hypertensive patients with insulin resistance or
Hisato Takagi et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 36(4), 368-373 (2012-12-14)
A recent meta-analysis of randomized head-to-head trials suggests that therapy with telmisartan, an angiotensin II receptor blocker (ARB) and partial agonist of peroxisome proliferator-activated receptor-gamma, may increase adiponectin levels more strongly than other ARB therapies. Therefore, telmisartan would be expected
Muralikrishna Gangadharan Komala et al.
PloS one, 9(11), e108994-e108994 (2014-11-05)
Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. Drugs inhibiting this transporter have recently been approved for clinical use and have been suggested to have
Page 1 of 3
Page 1 of 3